DANICHI YOSHIDA: Open Payments
NPI 1679971352 · NEWPORT BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,198 in 157 payments from 20 companies in 2025. Trend: 2023 $3,728 · 2024 $4,142 · 2025 $4,198
Food & beverage: $4,183Travel & lodging: $15
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 17 | $634 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $611 |
| Neurocrine BioSciences, Inc. | 16 | $593 |
| Otsuka America Pharmaceutical, Inc. | 11 | $381 |
| Alkermes, Inc. | 15 | $258 |
| Janssen Pharmaceuticals, Inc | 8 | $239 |
| Axsome Therapeutics, Inc. | 10 | $233 |
| E.R. Squibb & Sons, L.L.C. | 5 | $212 |
| Lundbeck LLC | 10 | $211 |
| Teva Pharmaceuticals USA, Inc. | 8 | $169 |
Products named: CAPLYTA, INGREZZA, HETLIOZ, REXULTI, SPRAVATO, Auvelity, FANAPT, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
